We examined the utilization patterns of topical corticosteroid (TCS) products from 2017 through 2021 from U.S. outpatient retail and mail order pharmacies to provide context for the evaluation of safety concerns associated with TCS. We used the Symphony Health MetysTM database to obtain national estimates of single-ingredient TCS prescriptions dispensed, and information on prescriber specialties who prescribed these products. TCS potency classes were assigned into seven categories ranging from super-high potency (class I) to least potent (class VII). We also used the Symphony Health Integrated Dataverse (IDV®) to characterize the length of therapy for selected single-ingredient TCS in a study sample stratified by potency class. To obtain information on diagnoses associated with the use of single-ingredient TCS stratified by patient age, we used Syneos Health Research & Insights LLC., TreatmentAnswers™ with Pain Panel, a U.S. office-based healthcare provider survey database. Overall, dispensed prescriptions for TCS increased by 8% from nearly 30 million prescriptions in 2017 to 32 million prescriptions in 2021. During the study period, for the lower-mid strength class V products (range: 34-35% annually) and super-potent class I products (range: 25-29% annually) were the most commonly dispensed TCS prescriptions. In 2021, among all TSC products, triamcinolone acetonide 0.1% cream (class V TCS, 31%) was the most commonly dispensed corticosteroid, followed by hydrocortisone 2.5% cream (class VII TCS, 10%), and clobetasol propionate 0.05% cream (class I TCS, 8%) in 2021. The dermatology specialty group accounted for the highest volume of dispensed prescriptions (36%), followed by family/general practice (27%) and internal medicine (10%). Across all age groups, hydrocortisone and triamcinolone acetonide were two of the top three prescribed TCS. Mometasone was one of the top three TCS among patients <17 years old patients. Clobetasol was one of the top three TCS among patients 17 years and older. Between 2017-2021, “atopic dermatitis” and “unspecified contact dermatitis” were the most common diagnoses associated with mentions of triamcinolone and hydrocortisone in pediatric and adult patients; however, clobetasol was more commonly mentioned in association with the diagnoses of “psoriasis” for patients aged 17 and older. We also examined the length of therapy and potency class for a sample of patients with a TCS prescription claim adjudicated in the first quarter of 2021. These patients were followed for 12 months through February 2022. The largest proportion of patients (58%) had a length of therapy of ≤30 days, and of these patients, 40% were dispensed a class V TCS. Conversely, 14% of patients had a length of therapy >90 days and almost half of the patients were dispensed a super-potent class I TCS. In conclusion, findings from the utilization analysis of single-ingredient TCS are important to be considered in the evaluation of adverse events related to TCS and in the development of mitigation strategies.